EVERIO AIRMASTER Inhalation powder, pre-dispensed 50mcg/500mcg/dose 60 doses
Everio Earmaster is indicated in adults and adolescents aged 12 years and older. Asthma. Everio Earmaster is indicated for the regular treatment of asthma when a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate: - patients inadequately controlled on inhaled corticosteroids and an inhaled short-acting β2 agonist as needed - or patients adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist. Chronic obstructive pulmonary disease (COPD). Everio Earmaster is indicated for the symptomatic treatment of patients with COPD with FEV1 < 60% predicted normal (before bronchodilator), with a history of repeated exacerbations and with significant symptoms on regular bronchodilator therapy. Salmeterol (as salmeterol xinafoate)/Fluticasone propionate 50 micrograms/500 micrograms/dose
